Cell kinetics as a prognostic indicator in node-negative breast cancer
- PMID: 2767105
- DOI: 10.1016/0277-5379(89)90410-0
Cell kinetics as a prognostic indicator in node-negative breast cancer
Abstract
The consistency of the prognostic role of cell kinetics (evaluated as the [3H]thymidine labeling index, LI) over a period of years has been assessed in 354 patients with resectable node-negative breast cancer subjected only to Halsted or modified radical mastectomy. The risk of disease recurrence and death was proportional to LI values and the pattern was superimposable, regardless of menopausal status, in the two consecutive case series entered in this retrospective study. In particular, tumors with high LI (greater than 2.8%) had a higher 6-year probability (41% vs. 25%, P less than 0.0001) of manifesting local-regional and distant metastases and of dying (19% vs. 5%, P = 0.0005) as compared to tumors with low LI. In tumors with high LI the risk of relapse within the first 2 years from mastectomy was twofold compared to that of tumors with low LI. Multiple regression analysis showed that LI also retained its prognostic significance in both relapse-free and overall survival when tumor size and estrogen receptor status were considered. The present findings confirm that LI can substantially contribute to the selection of high risk node-negative patients who could be candidates for adjuvant chemotherapy.
Similar articles
-
3H-thymidine-labeling index as a prognostic indicator in node-positive breast cancer.J Clin Oncol. 1990 Aug;8(8):1321-6. doi: 10.1200/JCO.1990.8.8.1321. J Clin Oncol. 1990. PMID: 2380758
-
Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy.J Clin Oncol. 1993 Jun;11(6):1150-5. doi: 10.1200/JCO.1993.11.6.1150. J Clin Oncol. 1993. PMID: 8501501
-
p53 as an independent prognostic marker in lymph node-negative breast cancer patients.J Natl Cancer Inst. 1993 Jun 16;85(12):965-70. doi: 10.1093/jnci/85.12.965. J Natl Cancer Inst. 1993. PMID: 8496982
-
Prognostic factors in resectable breast cancer.Semin Oncol. 1991 Apr;18(2 Suppl 4):53-7. Semin Oncol. 1991. PMID: 2031198 Review.
-
Low risk of locoregional recurrence of primary breast carcinoma after treatment with a modification of the Halsted radical mastectomy and selective use of radiotherapy.Cancer. 1999 Apr 15;85(8):1773-81. Cancer. 1999. PMID: 10223572 Review.
Cited by
-
Ki-S1, a novel proliferative marker: flow cytometric assessment of staining in human breast carcinoma cells.Br J Cancer. 1993 Apr;67(4):657-62. doi: 10.1038/bjc.1993.122. Br J Cancer. 1993. PMID: 7682430 Free PMC article.
-
Randomised clinical trial of adjuvant chemotherapy in patients with node-negative, fast-proliferating breast cancer.Drugs. 1993;45 Suppl 2:68-74; discussion 73-4. doi: 10.2165/00003495-199300452-00011. Drugs. 1993. PMID: 7693425 Clinical Trial.
-
Genetic evolution of breast cancers. III: Age-dependent variations in the correlations between biological indicators of prognosis.Breast Cancer Res Treat. 1995 Apr;34(1):25-33. doi: 10.1007/BF00666488. Breast Cancer Res Treat. 1995. PMID: 7749157
-
Comparison between different cell kinetic variables in human breast cancer.Cell Prolif. 2000 Apr;33(2):75-89. doi: 10.1046/j.1365-2184.2000.00165.x. Cell Prolif. 2000. PMID: 10845252 Free PMC article.
-
Endocrine therapy for advanced breast cancer: a review.Breast Cancer Res Treat. 1992;21(1):15-26. doi: 10.1007/BF01811960. Breast Cancer Res Treat. 1992. PMID: 1382723 Review.
Publication types
MeSH terms
LinkOut - more resources
Medical